Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia - PubMed (original) (raw)
Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia
T Miyamoto et al. Br J Haematol. 1995 Sep.
Abstract
Peripheral blood stem cells (PBSC) have been used increasingly for haemopoietic reconstitution after marrow-ablative chemotherapy in patients with acute leukaemia because of the possibility that there is a lower risk of leukaemic contamination. We have developed a titration assay using a competitive reverse transcriptase polymerase chain reaction (RT-PCR) which is able to estimate the number of AML1/ETO transcripts so that minimal residual disease (MRD) can be monitored quantitatively in patients with t(8;21) acute myelogenous leukaemia (AML). Using a qualitative RT-PCR method, AML1/ETO transcripts could be detected in all samples from 15 first PBSC harvests and 11 second PBSC harvests obtained from 15 patients with t(8;21) AML. With our competitive RT-PCR assay, the number of AML1/ETO transcripts was found to be lower in the second PBSC harvest than that in the first in every individual. Furthermore, MRD in PBSC harvests was less than that in the corresponding bone marrow obtained on the day of PBSC collection in the individual patients studied. In 10 patients who received autologous blood stem cell transplantation (ABSCT), we could not find a relationship between the number of AML1/ETO transcripts in the infused PBSC harvests and the clinical outcome after ABSCT. The present study clearly indicates that although PBSC harvests collected after consolidation chemotherapy are contaminated by leukaemic cells, the degree of leukaemic contamination may decrease as chemotherapy is repeated. The mobilization of PBSC by repeated chemotherapy may provide an advantageous source of haemopoietic stem cells for ABSCT.
Similar articles
- Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia.
Miyamoto T, Nagafuji K, Harada M, Niho Y. Miyamoto T, et al. Leuk Lymphoma. 1997 Mar;25(1-2):69-75. doi: 10.3109/10428199709042497. Leuk Lymphoma. 1997. PMID: 9130615 Review. - Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y. Miyamoto T, et al. Blood. 1996 Jun 1;87(11):4789-96. Blood. 1996. PMID: 8639850 - Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL, Chan V, Wong KF, Chan TK. Kwong YL, et al. Cancer. 1995 Feb 1;75(3):821-5. doi: 10.1002/1097-0142(19950201)75:3<821::aid-cncr2820750312>3.0.co;2-z. Cancer. 1995. PMID: 7828132 - Evaluation of leukaemic contamination in peripheral blood stem cell harvests by reverse transcriptase polymerase chain reaction.
Nagafuji K, Harada M, Takamatsu Y, Eto T, Teshima T, Kamura T, Okamura T, Hayashi S, Akashi K, Murakawa M, et al. Nagafuji K, et al. Br J Haematol. 1993 Nov;85(3):578-83. doi: 10.1111/j.1365-2141.1993.tb03351.x. Br J Haematol. 1993. PMID: 7510991 - The AML1 and ETO genes in acute myeloid leukemia with a t(8;21).
Nucifora G, Rowley JD. Nucifora G, et al. Leuk Lymphoma. 1994 Aug;14(5-6):353-62. doi: 10.3109/10428199409049690. Leuk Lymphoma. 1994. PMID: 7812194 Review.
Cited by
- The role of the AML1 transcription factor in leukemogenesis.
Lorsbach RB, Downing JR. Lorsbach RB, et al. Int J Hematol. 2001 Oct;74(3):258-65. doi: 10.1007/BF02982058. Int J Hematol. 2001. PMID: 11721960 Review. - Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M. Eto T, et al. Int J Hematol. 2013 Aug;98(2):186-96. doi: 10.1007/s12185-013-1378-9. Epub 2013 Jun 11. Int J Hematol. 2013. PMID: 23754766 - Oncolytic virotherapy for hematological malignancies.
Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Bais S, et al. Adv Virol. 2012;2012:186512. doi: 10.1155/2012/186512. Epub 2011 Oct 29. Adv Virol. 2012. PMID: 22312362 Free PMC article. - AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
Miyamoto T, Weissman IL, Akashi K. Miyamoto T, et al. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6. doi: 10.1073/pnas.97.13.7521. Proc Natl Acad Sci U S A. 2000. PMID: 10861016 Free PMC article. - Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia.
Guinn BA, Mohamedali A, Mills KI, Czepulkowski B, Schmitt M, Greiner J. Guinn BA, et al. Biomark Insights. 2007 Feb 14;2:69-79. Biomark Insights. 2007. PMID: 19662193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical